42 results about "Immunomodulin" patented technology

Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.

The invention discloses an application of a recombined ganoderma lucidum immunomodulatory protein in preparing a drug for treating parkinsonism. In-vivo animal tests show that the recombined ganoderma lucidum immunomodulatory protein can improve the behavioral disorder of a Parkinson animal model, has a certain neuroprotective effect on brain tissue dopaminergic neuron cell of the Parkinson animal model, and can prevent and treat parkinsonism.

The invention relates to an application of a recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure. According to the invention, a rat cardiac failure model is established by intraperitoneal injection of adriamycin amycin (ADR) to study the curative effect of rLZ-8 to chronic cardiac failure. Experimental research results show that rLZ-8 can remarkably improve the cardiac function of the rat cardiac failure model, reduce the rate of myocardial apoptosis, reduce expression of relevant apoptin in myocardial cells (caspase3 and caspase9) and increase the survival rate of rats with chronic heart failure.

Provided are immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infections agents containing nucleic acid encoding the immunomodulatory proteins. In some embodiments, the immunomodulatory proteins are secretable. In some embodiments, the immunomodulatory proteins are transmembrane proteins that are surfaceexpressed. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

Provided are transmembrane immunomodulatory proteins, nucleic acids encoding such proteins and cells engineered with the proteins. The transmembrane immunomodulatory proteins and engineered cells provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

The invention provides a method of producing a non-immunogenic (bio)engineered tissue from pluripotent stem cells or pluripotent stem cell derivatives, the respective cells being deficient of MHC class I molecules and comprising an immunomodulatory protein on their surface, wherein the method comprises inducing the differentiation of the pluripotent stem cells into a cell type that is essential for the function of the engineered tissue under conditions that also allow the formation of the engineered tissue, thereby rendering the engineered tissue to be non-immunogenic to a recipient of the engineered tissue. The present invention further relates to an engineered tissue, a pharmaceutical composition comprising the engineered tissue, medical treatments using the engineered tissue and uses of the engineered tissue.

Provided are immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

Provided are plasmid vector constructs encoding multiple immunomodulatory proteins where each protein or component thereof can be expressed utilizing appropriate promotors and/or translation modifiers. Additional immunomodulatory proteins and genetic adjuvants containing shared tumor antigens can be added to further therapeutic potential as well as allow tracking of therapeutic treatment. Also provides are methods of expressing the plasmid constructs.

The invention is applicable to the technical field of gene engineering. The invention provides an immunomodulatory protein mutant and a nucleotide sequence thereof, a recombinant plasmid vector, an engineering bacterium, a construction method and application. The amino acid sequence of the immunomodulatory protein mutant is obtained by mutating phenylalanine at the 8th site into tryptophan on thebasis of the amino acid sequence of immunomodulatory protein LZ-8 shown as SEQ ID NO.1, and the mutated amino acid sequence is shown as SEQ ID NO.2. According to the invention, the thermal stability of the recombinant LZ-8 and the stability of the recombinant LZ-8 patent medicine are further improved on the basis that the immunomodulatory activity and the anti-tumor activity are basically unchanged; on one hand, the heat stability of the immunomodulatory protein mutant is greatly improved, and compared with wild type LZ-8, the F8W phase transition temperature Tm is increased by 1.86 DEG C, andthe phase transition enthalpy value delta H is increased by 39.19 kJ/mol; and on the other hand, the immunomodulatory protein mutant has immunomodulatory activity and anti-tumor activity consistent with those of wild type LZ-8, and has higher application and development value compared with the prior art.

The invention discloses application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in androgenetic alopecia. In-vivo animal model experiments show that the recombinant ganoderma lucidum immunoregulatory protein is capable of improving depilation of an androgenetic alopecia anomal model and can be used for preventing and treating androgenetic alopecia. The recombinant ganoderma lucidum immunoregulatory protein disclosed by the invention is a high-purity protein substance prepared through a recombination technology and a yeast cell eukaryotic expression system.

The invention belongs to the field of biotechnology and immunology, and particularly relates to a duck-derived innate immunomodulatory protein DDX3X for regulating and controlling an innate immune signal pathway in duck embryo fibroblasts (DEF), participating in antiviral reaction and playing a role in duck antiviral infection. It is proved in the DEF that overexpression of duck-derived DDX3X caninduce generation of duck I-type interferon by activating transcription factors including IRF1 and Nf-kappa B; after the background expression of DDX3X is interfered, the activity of poly(I: C) and DTMUV induced I-type interferon is also obviously reduced; and the overexpression of DDX3X can be used for remarkably inhibiting the proliferation of the DTMUV (Duck tembusu virus). The invention further discloses that the duck-derived DDX3X is expected to become a novel target for treating duck inflammatory diseases, and can be applied to the preparation of drugs with the effect of inhibiting DTMUVproliferation; the duck-derived DDX3X can also be used as an immunomodulator for duck virus diseases.

The subjects of the invention are a cancer health caring food combination determining method and a non-instantaneous computer readable storage medium. The invention discloses the cancer health caringfood combination determining method and the non-instantaneous computer readable storage medium for utilization of persons with cancers as possible. The cancer health caring food combination determining method comprises the following steps of: a nucleic acid detecting step, detecting the nucleic acid in a biological sample, and determining a possibility of affecting the cancer according to the detecting result of the nucleic acid; a cancer detecting step, detecting a tumor index and at least one health index in a blood sample, and determining a fact that the cancer is not affected according toa detecting result of a tumor index; and a cancer health caring food combination determining step, determining the cancer health caring food combination according to the cancer affecting possibility in the nucleic acid detecting step and at least one health index in the cancer detecting step, wherein the cancer health caring food combination comprises multiple kinds of health caring food, and at least one kind of health caring food is an immunomodulatory protein or a compound of the immunomodulatory protein.

Provided are expression vector constructs encoding multiple immunomodulatory proteins where each protein or component thereof can be expressed utilizing appropriate promoters and/or translation modifiers. Additional immunomodulatory proteins and genetic adjuvants containing shared tumor antigens can be added to further therapeutic potential as well as allow tracking of therapeutic treatment. Alsoprovided are methods of use for the expression vectors.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.